SCHEMBL1834641

SCHEMBL1834641

Cc1ccc(C(=O)O)c(C)c1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLCN2 P51788 4/20 0.47
TTR P02766 3/20 0.46
NR4A1 P22736 2/20 0.46
MEN1 O00255 2/20 0.46
ADORA3 P0DMS8 2/20 0.46
PTGS2 P35354 2/20 0.46
AKR1C3 P42330 2/20 0.46
KMT2A Q03164 2/20 0.46
AKR1B10 O60218 1/20 0.46
ABCB11 O95342 1/20 0.46
CHRM1 P11229 1/20 0.46
FABP2 P12104 1/20 0.46
RXRA P19793 1/20 0.46
TBXA2R P21731 1/20 0.46
PTGS1 P23219 1/20 0.46
PDE4A P27815 1/20 0.46
MAPK1 P28482 1/20 0.46
NR4A2 P43354 1/20 0.46
AKR1C2 P52895 1/20 0.46
AKR1C1 Q04828 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29814908 1.00 CLCN2 (0.47) CLCN2TTRNR4A1MEN1ADORA3
SCHEMBL109811 0.84 CLCN2 (0.49) CLCN2TTRNR4A1MEN1ADORA3
SCHEMBL4670497 0.83 TSHR (0.52) CLCN2TTRNR4A1MEN1ADORA3
SCHEMBL7924637 0.83 TSHR (0.47) CLCN2TTRNR4A1MEN1ADORA3
SCHEMBL31335879 0.81 CA1 (0.48) CLCN2TTRNR4A1PTGS2CYP1A2
SCHEMBL2496346 0.81 CYP1A2 (0.41) CLCN2TTRNR4A1MEN1ADORA3
SCHEMBL9685948 0.81 CLCN2 (0.46) CLCN2TTRNR4A1MEN1ADORA3
SCHEMBL6238744 0.81 CYP1A2 (0.41) CLCN2TTRNR4A1MEN1ADORA3
SCHEMBL28942795 0.81 CLCN2 (0.47) CLCN2TTRNR4A1MEN1ADORA3
SCHEMBL1398470 0.81 CA1 (0.48) CLCN2TTRNR4A1PTGS2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4027995-B1 HPK1 ANTAGONISTS AND USES THEREOF NIMBUS SATURN INC (US) 2026-05-27 EP disclosed
US-12215105-B2 HPK1 antagonists and uses thereof Nimbus Saturn, Inc. (US) 2025-02-04 US disclosed
US-20240025898-A1 HPK1 ANTAGONISTS AND USES THEREOF SCHRÖDINGER, INC. 2024-01-25 US disclosed
US-20240025898-A1 HPK1 ANTAGONISTS AND USES THEREOF SCHRÖDINGER, INC. 2024-01-25 US disclosed
US-20240025898-A1 HPK1 ANTAGONISTS AND USES THEREOF SCHRÖDINGER, INC. 2024-01-25 US disclosed
US-11548890-B1 HPK1 antagonists and uses thereof Nimbus Saturn, Inc. (US) 2023-01-10 US disclosed
US-11548890-B1 HPK1 antagonists and uses thereof Nimbus Saturn, Inc. (US) 2023-01-10 US disclosed
CN-114945366-A HPK1 antagonists and uses thereof 林伯士萨顿公司 2022-08-26 CN disclosed
EP-4027995-A1 HPK1 ANTAGONISTS AND USES THEREOF Nimbus Saturn, Inc. (US) 2022-07-20 EP disclosed
US-11078201-B2 Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrol[3,4-c]pyridin-1-ones as HPK1 antagonists Nimbus Saturn, Inc. (US) 2021-08-03 US disclosed
US-7754742-B2 Imidazole carboxamides ELI LILLY AND COMPANY (US) 2010-07-13 US disclosed
WO-2010009062-A1 IMIDAZOLE CARBOXAMIDES ELI LILLY AND COMPANY (US) 2010-01-21 WO disclosed
US-20100016373-A1 IMIDAZOLE CARBOXAMIDES ELI LILLY AND COMPANY 2010-01-21 US disclosed
US-20060293264-A1 STAT3 decoy oligonucleotides and uses therefor NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2006-12-28 US disclosed
WO-2006012625-A2 STAT3 DECOY OLIGONUCLEOTIDES AND USES THEREFOR UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2006-02-02 WO disclosed
WO-2001083420-A2 METHOD OF MAKING SUBSTITUTED DIHALO AROMATIC ACID CHLORIDES OCCIDENTAL CHEMICAL CORPORATION (US) 2001-11-08 WO disclosed
US-6225514-B1 A MIXTURE OF AN AROMATIC HYDROCARBON, ESTER, NITRILE OR HALOGENATED AROMATIC, A HALOGENATING AGENT AND A STABLE ACID,AND CORROSION RESISTANT, HETEROGENEOUS, SOLID ACID CATALYST OF ?DOPED? MIXED OXIDES; BY-PRODUCT INHIBITION OCCIDENTAL CHEMICAL CORPORATION 2001-05-01 US disclosed
US-6211399-B1 AROMATIC COMPOUND IS REACTED WITH A CHLORINATING AGENT OR A BROMINATING AGENT IN THE PRESENCE OF ABOUT 0.1 TO ABOUT 10 MOLE % OF A LEWIS ACID CATALYST AT A TEMPERATURE OF AMBIENT TO ABOUT 100 DEGREES C AND A PRESSURE OF 10 TO 100 PSI OCCIDENTAL CHEMICAL CORPORATION 2001-04-03 US disclosed
US-6124512-A HETEROGENEOUS CATALYST. OCCIDENTAL CHEMICAL CORPORATION (US) 2000-09-26 US disclosed
US-6118018-A Chlorination and bromination of aromatic compounds at atmospheric pressure OCCIDENTAL CHEMICAL CORPORATION (US) 2000-09-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11548890-B1 HPK1 antagonists and uses thereof PDXK, HIPK1, PCK1 CLCN2 1877/4885TTR 4755/4885NR4A1 4499/4885
US-20100016373-A1 IMIDAZOLE CARBOXAMIDES CYP3A4, CYP2C9, AADAC CLCN2 1822/4885TTR 3561/4885NR4A1 3007/4885
US-20240025898-A1 HPK1 ANTAGONISTS AND USES THEREOF PDXK, HIPK1, PCK1 CLCN2 1877/4885TTR 4755/4885NR4A1 4499/4885
US-11078201-B2 Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrol[3,4-c]pyridin-1-ones as HPK1 antagonists HIPK1, PDXK, IP6K1 CLCN2 1632/4885TTR 4597/4885NR4A1 2846/4885
US-12215105-B2 HPK1 antagonists and uses thereof PDXK, HIPK1, PCK1 CLCN2 1877/4885TTR 4755/4885NR4A1 4499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.